-
目前,慢性心力衰竭(chronic heart failure,CHF)的发病率呈现上升趋势,病死率仍然很高,CHF发生时,除神经内分泌的过度激活外,还存在着广泛的免疫活动异常、血脂代谢紊乱、炎性系统的慢性激活、单核-巨噬细胞和淋巴细胞活化等[1]。门诊、急诊上CHF患者不断增加,一般病程高危,故早期诊断、及时治疗和改善症状是延长患者寿命的重要课题,为此,本研究进行了165例CHF患者血脂、血浆N氨基末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-ProBNP)、心肌肌钙蛋白I(cardiac troponin I,CTnI)和高敏C反应蛋白(high sensitive C-reaction protein,hs-CRP)水平测定的临床分析。
-
165例CHF患者血脂水平较60名正常对照者明显降低,以TC和TG降低最为明显,其次为HDL-C和LDL-C;正常对照者血浆生物标志物随LVEF的降低而逐步升高,以Ⅳ级49例CHF患者的升高最为显著(表 1)。165例CHF患者和60名正常对照者的血脂水平比较,差异有统计学意义(TC:tⅡ=2.214,P<0.05;tⅢ=2.873,P<0.01;tⅣ=3.146,P<0.01;TG:tⅡ=2.167,P<0.05;tⅢ=2.863,P<0.01;tⅣ=3.063,P<0.01;LDL-C:tⅡ=2.147,P<0.05;tⅢ=2.056,P<0.05;tⅣ=2.184,P<0.05;HDL-C:tⅡ=2.137,P<0.05;tⅢ=2.256,P<0.05;tⅣ=3.148,P<0.01);165例CHF患者和60名正常对照者的生物标志物比较,差异有统计学意义(NT-proBNP:tⅡ=2.096,P>0.05;tⅢ=2.813,P<0.01;tⅣ=4.135,P<0.001;CTnI:tⅡ=2.736,P<0.01;tⅢ=2.962,P<0.01;tⅣ=3.816,P<0.001;hs-CRP:tⅡ=2.103,P<0.05;tⅢ=2.956,P<0.01;tⅣ=4.452,P<0.001)。
组别 例数 血脂水平(mmol/L) 血浆生物标志物 TC TG LDL-C HDL-C NT-proBNP(pg/ml) CTnI(ng/ml) hs-CRP(pg/ml) 正常对照者 60 4.83±1.51 2.19±0.95 2.94±1.00 1.58±0.39 250.22±113.60 0.012±0.006 2.25±0.48 CHF患者 Ⅰ级 59 4.26±1.40 1.85±0.94 2.43±0.87 1.01±0.31 263.26±121.34 0.048±0.010 3.25±1.30 Ⅲ级 57 4.10±1.43 1.66±0.80 2.53±0.98 0.94±0.28 364.27±176.65 0.065±0.012 4.56±1.58 Ⅳ级 49 3.90±1.22 1.33±0.82 2.34±0.84 0.81±0.21 483.26±201.34 0.087±0.015 7.86±2.67 注:表中,CHF:慢性心力衰竭;TC:总胆固醇;TG:甘油三酯;LDL-C:低密度脂蛋白胆固醇;HDL-C:高密度脂蛋白胆固醇;NT-proBNP:血浆N氨基末端脑钠肽前体;CTnI:心肌肌钙蛋白I;hs-CRP:高敏C反应蛋白。 表 1 165例CHF患者和60名正常对照者的血脂和血浆生物标志物水平
(x±s) Table 1. The serum blood lipid and plasma biomarkers levels in 165 patients with chronic heart failure and 60 healthy controls
(x±s)
慢性心力衰竭患者血脂、血浆NT-ProBNP、CTnI和hs-CRP水平测定的临床分析
The clinical analysis of blood lipid and plasma NT-proBNP, CTnI and hs-CRP levels determined in patients with chronic heart failure
-
摘要:
目的 测定慢性心力衰竭(CHF)患者的血脂、血浆N氨基末端脑钠肽前体(NT-ProBNP)、心肌肌钙蛋白I(CTnI)和高敏C反应蛋白(hs-CRP)水平并进行临床分析。 方法 采用生化法、荧光免疫分析法和放射免疫分析法测定165例CHF患者和60名正常对照者的血脂和血浆NT-ProBNP、CTnI和hs-CRP水平,并进行比较性分析。 结果 165例CHF患者血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平较60名正常对照者明显降低(TC:tⅡ=2.214,P<0.05;tⅢ=2.873,P<0.01;tⅣ=3.146;P<0.01;TG:tⅡ=2.167,P<0.05;tⅢ=2.863,P<0.01;tⅣ=3.063,P<0.01;LDL-C:tⅡ=2.147,P<0.05;tⅢ=2.056,P<0.05;tⅣ=2.184,P<0.05;HDL-C:tⅡ=2.137,P<0.05;tⅢ=2.256,P<0.05;tⅣ=3.148,P<0.01)。在生物标志物的测定中,165例CHF患者的血浆NT-ProBNP、CTnI和hs-CRP水平与正常对照者之间的差异有统计学意义(NT-proBNP:tⅡ=2.096,P>0.05;tⅢ=2.813,P<0.01;tⅣ=4.135,P<0.001;CTnI:tⅡ=2.736,P<0.01;tⅢ=2.962,P<0.01;tⅣ=3.816,P<0.001;hs-CRP:tⅡ=2.103,P<0.05;tⅢ=2.956,P<0.01;tⅣ=4.452,P<0.001),而且随左心室射血功能(LVEF)的降低而逐步升高。 结论 CHF患者血脂水平(TC、TG、LDL-C和HDL-C)随LVEF的降低而降低,具有血脂代谢紊乱的现象;血浆生物标志物水平(NT-ProBNP、CTnI和hs-CRP)随LVEF的降低而升高。 Abstract:Objective To measure the levels of blood lipid and plasma N-terminal pro-brain natriuretic peptide(NT-proBNP), cardiac troponin I(CTnI) and high sensitive C-reaction protein(hs-CRP) in patients with chronic heart failure(CHF), and carry out clinical analysis. Methods The blood lipid and plasma NT-proBNP, CTnI and hs-CRP levels in 165 patients with CHF and 60 controls were analyzed by chemistry, fluorescent immunoassay and radioimmunoassay, and then the results were analyzed and compared. Results The serum TC, TG, LDL-C and HDL-C levels in 165 patients with CHF were significantly lower than those of 60 controls(TC:tⅡ=2.214, P < 0.05; tⅢ=2.873, P < 0.01; tⅣ=3.146; P < 0.01; TG:tⅡ=2.167, P < 0.05; tⅢ=2.863, P < 0.01; tⅣ=3.063, P < 0.01; LDL-C:tⅡ=2.147, P < 0.05; tⅢ=2.056, P < 0.05; tⅣ=2.184, P < 0.05; HDL-C:tⅡ=2.137, P < 0.05; tⅢ=2.256, P < 0.05; tⅣ=3.148, P < 0.01). In biomarkers determining, the plasma NT-proBNP, CTnI and hs-CRP levels in 165 patients with CHF were significantly higher than those of 60 controls(NT-proBNP:tⅡ=2.096, P > 0.05; tⅢ=2.813, P < 0.01; tⅣ=4.135, P < 0.001; CTnI:tⅡ=2.736, P < 0.01; tⅢ=2.962, P < 0.01; tⅣ=3.816, P < 0.01 and hs-CRP:tⅡ=2.103, P < 0.05; tⅢ=2.956, P < 0.01; tⅣ=4.452, P < 0.001), and the plasma three biomarker levels were increased with decreasing left ventricular ejection function(LVEF). Conclusion The blood lipid(TC, TG, LDL-C and HDL-C) levels were decreased with decreasing LVEF and showing abnormal metabolism, but the plasma biomarkers levels were increased with decreasing LVEF. -
表 1 165例CHF患者和60名正常对照者的血脂和血浆生物标志物水平
(x±s) Table 1. The serum blood lipid and plasma biomarkers levels in 165 patients with chronic heart failure and 60 healthy controls
(x±s) 组别 例数 血脂水平(mmol/L) 血浆生物标志物 TC TG LDL-C HDL-C NT-proBNP(pg/ml) CTnI(ng/ml) hs-CRP(pg/ml) 正常对照者 60 4.83±1.51 2.19±0.95 2.94±1.00 1.58±0.39 250.22±113.60 0.012±0.006 2.25±0.48 CHF患者 Ⅰ级 59 4.26±1.40 1.85±0.94 2.43±0.87 1.01±0.31 263.26±121.34 0.048±0.010 3.25±1.30 Ⅲ级 57 4.10±1.43 1.66±0.80 2.53±0.98 0.94±0.28 364.27±176.65 0.065±0.012 4.56±1.58 Ⅳ级 49 3.90±1.22 1.33±0.82 2.34±0.84 0.81±0.21 483.26±201.34 0.087±0.015 7.86±2.67 注:表中,CHF:慢性心力衰竭;TC:总胆固醇;TG:甘油三酯;LDL-C:低密度脂蛋白胆固醇;HDL-C:高密度脂蛋白胆固醇;NT-proBNP:血浆N氨基末端脑钠肽前体;CTnI:心肌肌钙蛋白I;hs-CRP:高敏C反应蛋白。 -
[1] 李海霞, 朱军, 罗心平, 等.慢性心力衰竭194例患者血脂分析的临床分析[J].中华现代内科学杂志, 2008, 5(3): 204-208.
[2] Rauchhaus M, Clark AL, DoehnerW, et al. The relationship between cholesterol and survival in patients with chronic heart failure[J]. J Am CollCardiol, 2003, 42(11): 1933-1940. doi: 10.1016/j.jacc.2003.07.016 [3] Rudolf J, Lewandrowski KB. Cholesterol, lipoprotein, High-sensitivity C-reactive protein, and other risk factors for atherosclerosis[J]. Clin Lab Med, 2014, 34: 113-127. doi: 10.1016/j.cll.2013.11.003 [4] Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis[J]. Lancet, 2000, 356(9233): 930-933. doi: 10.1016/S0140-6736(00)02690-8 [5] Yoneyama A, Koyama J, Tomita T, et al. Relationship of longitudinal function in patients with congestive heart failure assessed by strain Doppler imaging[J]. Int J Cardiol, 2008, 130(1): 56-63. [6] Miller WL, Hartman KA, Burritt MF, et al. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure[J]. Clin Chem, 2005, 51(3): 569-577. doi: 10.1373/clinchem.2004.041582 [7] Lorigados CB, Soriano FG, Szabo C. Pathomechanisms of myocardial dysfunction in sepsis[J]. Endocr Metab Immune Disord Drug Targets, 2010, 10(3): 274-284. doi: 10.2174/187153010791936856 [8] 卢丰才.肌钙蛋白I与肌钙蛋白T敏感性的比较和分析[J].医学检验与临床, 2010, 21(1): 41-43. doi: 10.3969/j.issn.1673-5013.2010.01.017
[9] Monteiro CM, PinheiroLF, Izar MC, et al. Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event[J]. Braz J Med Biol Res, 2010, 43(3): 297-302. doi: 10.1590/S0100-879X2010005000008 [10] Scrutinio D, Passantino A, Di Serio F, et al. High-sensitivity C-reactive protein predicts cardiovascular events and myocardial damage after surgery[J]. J Vasc Surg, 2011, 54(2): 474-479. doi: 10.1016/j.jvs.2011.01.041